Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease – Implications for Clinical Practice

In patients with type 2 diabetes (T2D), the excretion of glucose by the kidney with sodium-glucose cotransporter 2 (SGLT2) inhibitors lowers glycosylated haemoglobin (HbA1c) levels, decreases body weight and visceral adiposity, as well as improving cardio-renal haemodynamics. Currently, four SGLT2 i...

Descripción completa

Detalles Bibliográficos
Autor principal: Fitchett, David H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2018
Materias:
Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182918/
https://www.ncbi.nlm.nih.gov/pubmed/30349593
http://dx.doi.org/10.17925/EE.2018.14.2.40

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182918/
https://www.ncbi.nlm.nih.gov/pubmed/30349593
http://dx.doi.org/10.17925/EE.2018.14.2.40

Ejemplares similares